Han L, You Q J, Li Z, Yang H H, Fang H, Zhang Y
Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jul 7;52(7):497-500. doi: 10.3760/cma.j.issn.1673-0860.2017.07.004.
To evaluate the efficacy of treatment at 1 year after completing the 2-year specific sublingual immunotherapy in patients with allergic rhinitis (AR). A retrospective analysis of 124 patients with AR who were allergic to dust mite and treated in the First Affiliated Hospital of Wenzhou Medical University since 2012 was performed. All patients achieved sublingual immunotherapy (SLIT) for 2 years and had a regular follow-up over 1 year. Efficacy evaluation index such as VAS score, total nasal symptom score and total medication score were compared between the time of SLIT for 2 years, and 1 year after termination of SLIT. Paired t test was used for the comparison of scores. Compared with those before treatment, the VAS score, total nasal symptom score and total medication score at the time of SLIT for 2 years were significantly decreased in all patients with AR [(9.40±5.96) (24.78±6.36), (4.53±2.06) (9.51±2.02), (0.42±0.87) (3.02±0.41), value was 17.627, 24.600, 5.331, respectively, all <0.01]. Compared with 2 years SLIT treatment, VAS score and total nasal symptom score were significantly increased than 1 year after termination of immunotherapy [(12.52±6.92) (9.40±5.96), (5.30±2.36) (4.53±2.06), =5.199, 3.744, respectively, all <0.01], but the total medication score showed no significant difference [(0.34±0.84) (0.42±0.87), =-1.043, >0.05]. The symptoms after 2 years SLIT in patients with AR have been well controlled. One year after the termination of SLIT, there is a certain rebound in symptoms, 2 years SLIT may not be the ideal treatment cycle for AR.
评估变应性鼻炎（AR）患者完成2年特异性舌下免疫治疗后1年的治疗效果。对自2012年起在温州医科大学附属第一医院接受治疗的124例对尘螨过敏的AR患者进行回顾性分析。所有患者均接受了2年的舌下免疫治疗（SLIT），并进行了为期1年的定期随访。比较了SLIT治疗2年时与SLIT终止后1年时的视觉模拟评分（VAS）、总鼻症状评分和总用药评分等疗效评估指标。采用配对t检验比较评分。与治疗前相比，所有AR患者在SLIT治疗2年时的VAS评分、总鼻症状评分和总用药评分均显著降低[（9.40±5.96） （24.78±6.36），（4.53±2.06） （9.51±2.02），（0.42±0.87） （3.02±0.41），P值分别为17.627、24.600、5.331，均<0.01]。与SLIT治疗2年时相比，免疫治疗终止后1年时的VAS评分和总鼻症状评分显著升高[（12.52±6.92） （9.40±5.96），（5.30±2.36） （4.53±2.06），P分别为5.199、3.744，均<0.01]，但总用药评分无显著差异[（0.34±0.84） （0.42±0.87），P=-1.043，>0.05]。AR患者SLIT治疗2年后症状得到良好控制。SLIT终止1年后，症状有一定程度的反弹，2年SLIT可能不是AR的理想治疗周期。
